World Diabetes Industry Analyzed in New Research Study Now Available at MarketPublishers.com14 Feb 2012 • by Natalie Aster
LONDON – The prevalence of diabetes is reaching epidemic proportions from pole to pole. The global market for products in diabetes management is forecast to grow to over USD 114 billion by 2018. The bulk of product revenues come from three segments – test strips, insulin and anti-diabetic drugs – which will remain the largest sources of product revenues over the next decade. The most significant growth, however, is awaited from the nascent segment of continuous blood glucose monitors.
The U.S., followed by Europe, constitutes the largest regional market, with product revenues in diabetes management standing at roughly 37% of the global market, while growth is expected to emanate from the Asia-Pacific going forward.
New market research study “Analyzing the Global Diabetes Market” prepared by Aruvian’s R’search provides an all-encompassing picture of the global diabetes industry, which is examined through a market overview and an analysis of the market by drug classes (including novel emerging) and key molecules for diabetes treatment, as well as through industry segmentation and an analysis of the leading industry products. An analysis of the diabetes market in India and China is also included, along with an up-close look at industry research and development. Profiles of the top market players along with the overall competitive landscape, and future perspectives of the market are featured as well.
Companies mentioned in the report include: Eli Lilly & Co., Merck & Co., Novo Nordisk, Sanofi SA, Takeda Pharmaceutical Company.
Analyzing the Global Diabetes Market
Published: February, 2012
Price: US$ 500,00
More new market reports by the publisher can be found at Aruvian’s R’search page.